Navigation Links
Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
Date:6/19/2008

is press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include statements about future sales of Zevalin and the development of OPAXIO and pixantrone which include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with OPAXIO and pixantrone in particular, including, without limitation, the potential failure of these product candidates to prove safe and effective for treatment of non-small cell lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and sarcoma, determinations by regulatory, patent and administrative governmental authorities including but not limited to decisions regarding the review and approval of applications submitted to the FDA or the EMEA, competitive factors, technological developments, costs of developing, producing and selling Zevalin, OPAXIO and pixantrone, the outcome of clinical trial results for ongoing trials of our drugs, including pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Cell Therapeutics, Inc.

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Lindsey Jesch

T : 206.272.4347

F : 206.272.4434

E: media@ctiseattle.com

http://www.CellTherapeutics.com/media.htm

Investors Contact:

Cell Therapeutics, Inc.

Ed Bell

T: 206.272.4345

<
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
4. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
5. Pharmos Issues Letter to Shareholders
6. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
7. YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS
8. YM Biosciences announces adoption of renewed Shareholders Rights Plan
9. Isolagen, Inc. Reports Results of Shareholders Annual Meeting
10. CardioMag Announces Results of 2006 Annual Shareholders Meeting and Board Meeting
11. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... (Q2 2015: +14% CER / 20% of sales) led the regional performance ... , as well as solid contributions from Korea, India ... Middle East / Africa (Q2 ... , Turkey and the United Kingdom ... 11%, excluding U.S. HPV sales, on demand across all customer classes. The top ...
(Date:7/29/2015)...  AsureQuality and Ubiquitome have agreed to collaborate ... food and primary production sectors. The collaboration will ... the Freedom4. AsureQuality provides quality assurance ... shelf for producers, processors and Competent Authorities around ... control and pest management and surveillance programmes. ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... announced its GHS Label Guide . To align chemical container labeling with ... guide includes explanations of label components, an example of an accurate label, and ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE ... financial results will be released on Thursday, August 13, ... Eastern Time, Pfenex management will host a conference call ... update.  A press release outlining the financial results and ... call. Please call 1-866-376-8058 (US) or 1-412-542-4131 ...
Breaking Biology Technology:QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Brady Announces a New GHS Label Guide 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2
... announces that a new market research report is available ... http://www.reportlinker.com/p0288102/US-Vaccines-Market.html ... for vaccines is forecast to increase 5.5 percent annually ... has experienced dramatic growth due to increasing routine seasonal ...
... Fibrocell Science, Inc. (OTC Bulletin Board: ... of autologous cell therapies for aesthetic, medical and scientific ... , M.D., Ph.D., to its scientific advisory board. In ... Dr. Gruenwald is a biotechnology and genetic research expert. ...
... IRVINE, Calif., Sept. 7 ChromaDex Corporation (OTC Bulletin ... company which provides novel and innovative ingredients to the ... a clinical study at The University of Mississippi for ... based on the grant of an exclusive worldwide license ...
Cached Biology Technology:Reportlinker Adds US Vaccines Market 2Reportlinker Adds US Vaccines Market 3Reportlinker Adds US Vaccines Market 4Reportlinker Adds US Vaccines Market 5Reportlinker Adds US Vaccines Market 6Reportlinker Adds US Vaccines Market 7Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board 2Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board 3ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene 2ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene 3
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... which cancer cells travel from a tumor site and proliferate ... to cancer patients. According to the National Cancer Institute, most ... Virtually all types of cancer can spread to other parts ... are entrenched in the brain, patients typically have only a ...
... the sensitivity of Australia,s species and ecosystems to climate ... about biodiversity conservation. ,Climate change is likely to ... 2030, lead researcher, CSIRO,s Dr Michael Dunlop said.,By 2070, ... and widespread. Many of the environments our plants and ...
... Researchers at the National Institute of Standards and Technology ... candidate refrigerant fluids with low "global warming potential" (GWP) ... for many decades as well as other desirable ... the most extensive systematic search for a new class ...
Cached Biology News:Fighting melanoma's attraction to the brain 2Major changes needed to protect Australia's species and ecosystems 2New NIST screening method identifies 1,200 candidate refrigerants to combat global warming 2
Bag-1 (K-20)...
... PGE2-d4 contains 4 deuterium atoms at ... It is intended for use as an ... E2 (PGE2) by GC- or LC-mass spectrometry. ... products of arachidonic acid and one of ...
Deletions, insertions or substitutions. Mutations in plasmids of size up to 15 kb. Single or multiple mutations...
Request Info...
Biology Products: